These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2521518)

  • 21. Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs.
    Helbig B; Sauerbrei A; Klöcking R; Wutzler P; Wicht N; Wiedemann U; Herrmann G
    J Med Virol; 1987 Nov; 23(3):303-9. PubMed ID: 2828526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The characterization of EIAV reverse transcriptase and its inhibition by 5'-triphosphates of 2'-deoxyuridine analogs, PFA and PAA.
    Tao P; Zhang X; Quan K
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(3):130-4. PubMed ID: 1711694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides.
    Shirokova EA; Jasko MV; Khandazhinskaya AL; Ivanov AV; Yanvarev DV; Skoblov YS; Mitkevich VA; Bocharov EV; Pronyaeva TR; Fedyuk NV; Kukhanova MK; Pokrovsky AG
    J Med Chem; 2004 Jul; 47(14):3606-14. PubMed ID: 15214788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of HTLV-III/LAV replication by foscarnet.
    Sarin PS; Taguchi Y; Sun D; Thornton A; Gallo RC; Oberg B
    Biochem Pharmacol; 1985 Nov; 34(22):4075-9. PubMed ID: 2415134
    [No Abstract]   [Full Text] [Related]  

  • 25. Selection and characterization of mutant S49 T-lymphoma cell lines resistant to phosphonoformic acid: evidence for inhibition of ribonucleotide reductase.
    Albert DA; Gudas LJ
    J Cell Physiol; 1986 May; 127(2):281-7. PubMed ID: 2939095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine.
    Shiraki K; Ogino T; Yamanishi K; Takahashi M
    Biken J; 1983 Mar; 26(1):17-23. PubMed ID: 6312958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs.
    Field H; McMillan A; Darby G
    J Infect Dis; 1981 Feb; 143(2):281-5. PubMed ID: 6260876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properties of antiviral agents. 1.
    Nicholson KG
    Lancet; 1984 Sep; 2(8401):503-6. PubMed ID: 6147558
    [No Abstract]   [Full Text] [Related]  

  • 29. Phosphonoformate inhibits reverse transcriptase.
    Sundquist B; Oberg B
    J Gen Virol; 1979 Nov; 45(2):273-81. PubMed ID: 94344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antiviral activity of phosphonoacetic acid, phosphonopropionic acid, and trisodium phosphonoformate hexahydrate against herpesvirus hominis type 1 and type 2 in vitro].
    Thiel KD; Wutzler P; Sprössig M; Bertram D
    Pharmazie; 1982 Aug; 37(8):608. PubMed ID: 6292963
    [No Abstract]   [Full Text] [Related]  

  • 31. Phosphonoformic acid-inhibitable nucleotide incorporation as a measure of hepatitis B viral DNA polymerase activity.
    Lin HJ; Kwan JP; Wu PC; Chak W
    J Med Virol; 1983; 12(1):61-70. PubMed ID: 6225836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action of foscarnet against viral polymerases.
    Crumpacker CS
    Am J Med; 1992 Feb; 92(2A):3S-7S. PubMed ID: 1371038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Foscarnet.
    Lancet; 1985 Sep; 2(8456):648-9. PubMed ID: 2863637
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition of hepatitis-B-virus DNA polymerase by phosphonoformate: studies on its mode of action.
    Hess G; Arnold W; Meyer zum Büschenfelde KH
    J Med Virol; 1980; 5(4):309-16. PubMed ID: 6453206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Body burden" of phosphonoformic acid after topical and vaginal administration to rabbits and beagle dogs.
    Hussain AS; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1989 Feb; 11(2):111-4. PubMed ID: 2523506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herpes simplex type 1 defective interfering particles do not affect the antiviral activity of acyclovir, foscarnet and adenine arabinoside.
    Harmenberg JG; Svensson LT
    Acta Virol; 1988 Mar; 32(2):153-5. PubMed ID: 2899962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Na+-Pi cotransporter in small gut brush border by phosphonocarboxylic acids.
    Loghman-Adham M; Szczepanska-Konkel M; Yusufi AN; Van Scoy M; Dousa TP
    Am J Physiol; 1987 Feb; 252(2 Pt 1):G244-9. PubMed ID: 2950771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro recovery of resistant retrovirus isolates after exposure to phosphonoformate.
    Muratore O; Varnier OE; Raffanti SP; Schito GC
    Eur J Clin Microbiol; 1984 Oct; 3(5):447-9. PubMed ID: 6238823
    [No Abstract]   [Full Text] [Related]  

  • 39. 5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
    Wigerinck P; Pannecouque C; Snoeck R; Claes P; De Clercq E; Herdewijn P
    J Med Chem; 1991 Aug; 34(8):2383-9. PubMed ID: 1652017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs.
    Wondrak EM; Löwer J; Kurth R
    J Antimicrob Chemother; 1988 Feb; 21(2):151-61. PubMed ID: 2452149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.